Repligen Corporation
RGEN
Jodie situation report
Repligen Corporation's move is being confirmed by its market group.
RGEN accounts for 13.4% of the group's measured movement across 9.2 effective names. raw member direction is mixed; 10 of 10 SPY-adjusted paths align to the upside. Capital-flow agreement is 39%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
BIO, CRL, SHC moved materially before RGEN. RGEN crossed its material path threshold at 10:50 ET, 5 minutes after the first measured mover. MTD, WAT, DHR followed.
5 of 10 members in Healthcare Diagnostics are active. 0 of 1 disclosed connections are confirming.
- At least 7 of 10 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as BRKR begins moving with the group.
Invalidation: The live read weakens if participation falls to 3 of 10 members or fewer.
Who this business touches
The relationships behind RGEN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
MASSFiling-linked nameinvesteeAug 7, 2025 ▾
“Bioprocessing Analytics Portfolio On March 4, 2025, the Company completed its acquisition of 908 Devices Inc.’s (“908 Devices”) desktop portfolio of four devices for bioprocessing process analytical technology applications (“PAT Portfolio”).”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
RGEN is currently a Early Follower in the organic co-movement group Healthcare Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.